title: Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.
abstract: An assessment of the effective in vivo concentrations of antifungal drugs is important in determining their pharmacodynamics, and therefore, their optimal dosage regimen. Here we establish the effective in vivo concentration-based pharmacodynamics of three azole antifungal drugs (fluconazole, itraconazole, and ketoconazole) in a murine model of disseminated Candida albicans infection. A key feature of this study was the use of a measure of mycelial (m) growth rather than of yeast growth, and pooled mouse sera rather than synthetic media as a growth medium, for determining the minimum inhibitory concentrations (MICs) of azoles for C. albicans (denoted serum mMICs). The serum mMIC assay was then used to measure antifungal concentrations and effects as serum antifungal titers in the serum of treated mice. Both serum mMIC and sub-mMIC values reflected the effective in vivo serum concentrations. Supra-mMIC and mMIC effects exhibited equivalent efficacies and were concentration-independent, while the sub-mMIC effect was concentration-dependent. Following administration of the minimum drug dosage that inhibited an increase in mouse kidney fungal burden, the duration periods of these effects were similar for all drugs tested. The average duration of either the mMIC effect including the supra-mMIC effect, the sub-mMIC effect, or the post-antifungal effect (PAFE) were 6.9, 6.5 and 10.6 h, respectively. Our study suggests that the area under the curve for serum drug concentration versus time, between the serum mMIC and the sub-mMIC, and exposure time above the serum sub-mMIC after the mMIC effect, are major pharmacodynamic parameters. These findings have important implications for effective concentration-based pharmacodynamics of fungal infections treated with azoles.
authors.affiliation: Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan, katsuyuki.maki@astellas.com.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Maki
authors.forename: Shuji
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000465:Algorithms; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019540:Area Under Curve; D001393:Azoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D006207:Half-Life; D051379:Mice; D008811:Mice, Inbred DBA; D008826:Microbial Sensitivity Tests; D025282:Mycelium / Q000187:drug effects / Q000254:growth & development; D044967:Serum
chemical_list: D000935:Antifungal Agents; D001393:Azoles
references.citation: Microbiol Immunol. 2007;51(11):1053-9
references.pmid: 18037782
references.citation: Eukaryot Cell. 2003 Oct;2(5):1053-60
references.pmid: 14555488
references.citation: Antimicrob Agents Chemother. 1998 May;42(5):1105-9
references.pmid: 9593135
references.citation: Antimicrob Agents Chemother. 2007 Jan;51(1):35-9
references.pmid: 17101684
references.citation: Antimicrob Agents Chemother. 2008 Oct;52(10):3637-41
references.pmid: 18694949
references.citation: Antimicrob Agents Chemother. 1997 Jun;41(6):1392-5
references.pmid: 9174207
references.citation: Curr Drug Metab. 2011 May;12(4):313-28
references.pmid: 21395530
references.citation: Microbiol Immunol. 2008 Aug;52(8):383-91
references.pmid: 18667037
references.citation: Mol Biol Cell. 2008 Dec;19(12):5456-77
references.pmid: 18843050
references.citation: Clin Pharmacokinet. 2006;45(7):649-63
references.pmid: 16802848
references.citation: Antimicrob Agents Chemother. 2005 Aug;49(8):3171-7
references.pmid: 16048920
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):1108-11
references.pmid: 10722525
references.citation: Antimicrob Agents Chemother. 2001 Jul;45(7):2018-22
references.pmid: 11408217
references.citation: Antimicrob Agents Chemother. 2000 Oct;44(10):2715-8
references.pmid: 10991850
references.citation: Antimicrob Agents Chemother. 2003 Oct;47(10):3165-9
references.pmid: 14506026
references.citation: Scand J Infect Dis. 1999;31(5):501-4
references.pmid: 10576131
references.citation: Antimicrob Agents Chemother. 2003 Apr;47(4):1179-86
references.pmid: 12654644
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):137-42
references.pmid: 14693531
references.citation: Antimicrob Agents Chemother. 1999 Sep;43(9):2116-20
references.pmid: 10471550
references.citation: Microbiol Immunol. 2006;50(4):281-92
references.pmid: 16625050
references.citation: Antimicrob Agents Chemother. 1988 Jan;32(1):1-8
references.pmid: 2831809
references.citation: Antimicrob Agents Chemother. 2006 Oct;50(10):3312-6
references.pmid: 17005810
references.citation: J Antimicrob Chemother. 1994 Jul;34(1):93-100
references.pmid: 7961220
references.citation: Antimicrob Agents Chemother. 2003 Apr;47(4):1193-9
references.pmid: 12654646